NEW YORK (GenomeWeb) – Fluidigm today announced that it anticipates total fourth quarter 2015 revenue of between $30 million and $31 million, and full-year 2015 revenue of $114 million to $115 million, ahead of the consensus Wall St. estimates of $28.7 million for Q4 and $112.6 million for the full year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.